Joseph Powell, MD
Family Medicine · Hartsville, SCNPI 1255525820
Payments from drug & device makers
Across 116 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$377
- Boehringer Ingelheim$235
- AstraZeneca$192
- Pfizer$163
- Novo Nordisk$138
- Amgen$125
- plus $718 from 20 others
What the payments were for
- Speaking & faculty fees$603%
- Food & beverage$1,68386%
- Education$20611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $377 |
| Boehringer Ingelheim | 14 | $235 |
| AstraZeneca | 12 | $192 |
| Pfizer | 13 | $163 |
| Novo Nordisk | 10 | $138 |
| Amgen | 8 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $103 |
| Amarin Pharma, Inc. | 6 | $101 |
| Merck | 5 | $66 |
| GSK | 4 | $52 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Novartis | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| AbbVie | 3 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Bayer | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Viatris Specialty LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Abbott | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$1,949 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 469 | $251,603 |
| TrulicityDulaglutide | 91 | $94,848 |
| JardianceEmpagliflozin | 179 | $94,432 |
| OzempicSemaglutide | 76 | $91,505 |
| EntrestoSacubitril/Valsartan | 74 | $39,513 |
| MyrbetriqMirabegron | 67 | $37,315 |
| MounjaroTirzepatide | 28 | $35,734 |
| JanuviaSitagliptin Phosphate | 47 | $34,151 |
| LinzessLinaclotide | 43 | $30,272 |
| RexultiBrexpiprazole | 38 | $29,611 |
| TradjentaLinagliptin | 54 | $26,411 |
| Teriparatide | 13 | $25,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $25,085 |
| Repatha SureclickEvolocumab | 17 | $24,622 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $20,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $163 | $259,674484 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $235 | $142,681261 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $17 | $130,582119 claims |
| Novo NordiskOzempic | $138 | $91,50576 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $52 | $51,53676 claims |
| AbbVieLinzess, Creon | $36 | $48,50762 claims |
| NovartisEntresto | $44 | $39,51374 claims |
| Astellas Pharma US IncMyrbetriq | $377 | $37,31567 claims |
| MerckJanuvia | $66 | $34,15147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16 | $29,61138 claims |
| AstraZenecaFarxiga, Brilinta | $192 | $18,95557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Hartsville
- Abraham AreephanthuHartsville$22K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.